Bio-Rad to acquire MorphoSys’ AbD Serotec, 2/13:113
MorphoSys in December signed a definitive agreement to sell its AbD Serotec research and diagnostic antibody segment to Bio-Rad Laboratories.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Vitamin D test, 2/13:113
Diazyme Laboratories has received FDA 510(k) clearance to market its new 25-hydoxy vitamin D assay, which measures total true 25-hydroxy vitamin D levels in serum and plasma samples. The assay automates the removal of nonspecific protein binding and cross-reactivity that may occur in competing assays, thereby ensuring results will be precise and accurate.
Hemophilia genetics testing, 2/13:113
BloodCenter of Wisconsin’s Diagnostic Laboratories has expanded its genetic testing menu for hemophilia. Its new approach to hemophilia genetics allows BloodCenter to identify the genetic abnormality in greater than 95 percent of all hemophilia patients.
Human monoclonal antibodies for flow cytometry, 2/13:113
Beckman Coulter Life Sciences has added to its flow cytometry portfolio 14 new human monoclonal antibodies from Trillium Diagnostics. The analyte-specific reagents are highly specific, convenient, and flexible. Also offered is a new cell permeabilization reagent.
Trichomonas test, 2/13:113
Hologic has received FDA clearance to market its Aptima Trichomonas vaginalis assay on the company’s automated Panther system.
T. gondii products, 2/13:113
Meridian Life Science offers several new Toxoplasma gondii products.
Chembio: Positive data from syphilis test study, 2/13:112
Chembio Diagnostics reported that data from a study evaluating the sensitivity and specificity of the company’s point-of-care Dual Path Platform (DPP) rapid test for syphilis was recently published online in Clinical Infectious Diseases.
MDxHealth, Ghent form pharmacoepigenomics center, 2/13:112
MDxHealth has joined forces with Ghent University to establish NXTGNT, a pharmacoepigenomics center.
High-volume coagulation analyzer, 2/13:112
Siemens Healthcare Diagnostics Sysmex CS-5100 system, a random-access high-volume coagulation analyzer, is now available in Europe, Africa, Canada, Latin America, Australia, and New Zealand. It is equipped with multi-wavelength preanalytical sample integrity technology, enabling high-volume laboratories to achieve first-run accuracy by identifying and managing unsuitable test specimens before analysis.
Guideline on detecting fungi, 2/13:112
The Clinical and Laboratory Standards Institute has published “M54-APrinciples and Procedures for Detection of Fungi in Clinical Specimens-Direct Examination and Culture; Approved Guideline.” The document addresses the protocols for detecting fungi in clinical specimens and highlights direct microscopic examinations and fungal culturing methods.